9/10TH Conf./Cancer Therapy/Antibody/Immunoconjugates

9/10TH 会议/癌症治疗/抗体/免疫结合物

• 批准号: 6784118
• 负责人: DAVID M GOLDENBERG
• 金额: $ 0.5万
• 依托单位: CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-16 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6784118
• 关键词: antibody; immunoconjugates; meeting /conference /symposium; neoplasm /cancer radioimmunotherapy; neoplasm /cancer therapy; travel

DESCRIPTION (provided by applicant): Conference grant support is requested for the ninth and tenth conferences, which occur biennially and have been devoted to the use of radioimmunoconjugates in cancer imaging and therapy. Due to the regulatory approval of both naked antibodies (CD20 and HER2/neu) as well as drug-conjugated antibodies (Myelotarg), as well as a large number of other antibodies being in late-stage clinical development, the program is being broadened to include all potential antibody constructs, with emphasis on clinical studies. During the 3-day program, topics of molecular structure of therapeutic antibodies, applications and mechanisms of naked antibodies, drug and toxin conjugates, radioimmunoconjugates, cytokine fusion proteins, pretargeting methods, and anti-idiotype antibody vaccines will be covered, including brief overviews by leading investigators in these fields. However, the emphasis will be to attract proffered papers by new investigators in these areas, and permit a large number of oral and poster presentations over the 3-day period. As in the past, it is anticipated that the proceedings of the conferences will be published as supplements to major cancer journals, emphasizing the inclusion of new, original results. These proceedings therefore enjoy widespread availability and attention, thus attracting new investigators to participate in the conferences and in their published proceedings. The planning committee (partial list) represents leaders in these fields from academia, industry, and government. The conference chairman, Dr. Goldenberg, has secured two outstanding scientists as co-chairmen, Drs. Ralph Reisfeld (Scripps) and Edward Sausville (NCI).

描述（由申请人提供）：第九届和第十届会议请求会议拨款支持，该会议每两年举行一次，致力于放射免疫缀合物在癌症成像和治疗中的使用。 由于裸抗体（CD20 和 HER2/neu）以及药物偶联抗体（Myelotarg）以及大量其他处于后期临床开发阶段的抗体均获得了监管部门的批准，该计划正在扩大到包括所有潜在的抗体构建体，重点是临床研究。 在为期三天的课程中，将涵盖治疗性抗体的分子结构、裸抗体、药物和毒素缀合物、放射免疫缀合物、细胞因子融合蛋白、预靶向方法和抗独特型抗体疫苗的应用和机制等主题，包括简要概述这些领域的领先研究人员。 然而，重点是吸引这些领域的新研究人员提交论文，并允许在 3 天的时间内进行大量口头和海报展示。 与过去一样，预计会议记录将作为主要癌症期刊的增刊出版，强调包含新的原创结果。 因此，这些会议记录受到广泛关注和关注，从而吸引新的研究人员参加会议及其出版的会议记录。 规划委员会（部分名单）代表来自学术界、工业界和政府的这些领域的领导者。 会议主席戈登伯格博士聘请了两位杰出科学家作为联合主席。拉尔夫·赖斯菲尔德（斯克里普斯）和爱德华·索斯维尔（NCI）。